Toggle navigation
Home
Ask A Question
Ask
Answer Questions
Answer
Users
Support/FAQ
Login
Register
Preview 50% of the Answer Below
Due to formatting, images, tables, or paragraphs may be out of place or not shown. Rest assured that they will be included and formatted correctly in your purchased answer.
Details
Question Title:
Health Care
Go Back to the Question
Answer Preview
Biotechnology Organization: Motif Bio</span></p> <p><span class="s1"></span> </p> <p><span class="s1" <this="" essay="" will="" discuss="" the="" mission="" statement="" of="" motif="" bio,="" a="" clinical-stage="" biopharmaceutical="" company="" that="" serves="" as="" researcher="" and="" manufacturer="" antibiotic="" drugs="" combat="" multi-drug="" resistant="" bacteria,="" well="" activities="" organization="" role="" this="" plays="" in="" u.s.="" healthcare="" system.=""></span></p>This essay will discuss the mission statement of Motif Bio, a clinical-stage biopharmaceutical company that serves as a researcher and manufacturer of antibiotic drugs that combat multi-drug resistant bacteria, as well as the activities of the organization and the role that this organization plays in the U.S. healthcare system.<p></p><p><br></p><p></p><p><span class="s1">The mission of Motif Bio is to create novel antibiotics that are effective against infections caused by multi-drug resistant Gram-positive bacteria, such as MRSA. The company’s mission is especially timely, given the rapid increase in multi-drug resistant bacteria cases such as MRSA due to an increase in the misuse of antibiotics, and a growth in the complexity of the bacterial mutation environment. (Motif Bio, 2015)</span></p> <p><span class="s1"></span> </p> <p><span class="XX" <XXX="" organization’s="" main="" XXXXXXXXXX="" XXX="" in="" XXXXXXXX="" XXX="" development,="" XXXXXXXX="" XXXXXX,="" production,="" distribution,="" certification,="" XXXXXXXX="" XXXXXX="" recruitment.="" XXXXXXXX,="" the="" XXXXXXX="" invests="" XXXXXXX="" XXXXXXXXXX="" XXXXXXX="" its="" lead="" XXXXXXX="" candidate="" of="" iclaprim,="" for="" uses="" XXXX="" as="" XXXXX="" XXXXXXXXX="" XXXX="" XXXXXXXXX="" infections="" (absssi),="" XXXXXXXX="" XXXXXXXX="" pneumonia="" (habp),="" XXXXXXXX="" XXXXXXXXXX="" (XXXX).="" (XXXXX="" bio,="" XXXX)="" XXXX="" conducts="" trials="" to="" ensure="" XXXXX="" XXXXXXXX="" XXXX="" administration="" patients="" situations="" knee="" surgeries.="" example,="" date,="" has="" conducted="" XX="" nearly="" X,XXX="" healthy="" XXXXXXXXXX="" assess="" XXXXXXX="" effectiveness="" XXXX-XXXXXXX="" XXXX="" candidate.="" XXXXXXX="" revive-X,="" XXXXXX-X="" inspire="" which="" XXXXXX,="" XXXX="" vabp="" respectively.="" also="" produces="" distributes="" drugs,="" is="" responsible="" safe,="" XXXXXXXXX="" XXXX-XXXXXXXXX="" XXXXXXXXXX="" distribution="" XXXXX="" XXXXXXXXXXXX="" clinics="" XXXXXXXXX.="" XXXXX="" certify="" that="" XXXX="" can="" be="" distributed="" legally,="" XXXXXXXXXXXXX="" processes="" XXXXXXXXX="" infectious="" XXXXXXX="" (qidp)="" fda="" XXXXXXXXXXXXX.="" XXXX)="" XXXX,="" XXXXX="" properly="" XXXXXXXXXX="" public="" XXXXXXXXXX,="" XXXXX="" XXXXXXXX="" XXXXXX="" XXXXX="" XXXXXXXXX,="" tradeshow="" exhibitions="" lectures.="" XXXXXXX,="" XXXXXXXXXXX,="" order="" a="" diverse="" capable="" team="" comprising="" XXXXXXXXXXX,="" biochemists,="" bio-engineers="" XXXXXXX="" able="" XXXXXXX="" rigorous="" XXXXXXXXX="" XXXXXXX="" XXXXX="" anti-XXXXX-drug-resistant="" bacteria="" XXXX="" publish="" renowned="" journals="" XXXXXX="" XXXXX="" bio="" stays="" XX="" forefront="" XXXXXXXXXX="" XXXXXXXXXXXXXXXXX="" XXXXXXXX.=""></span></p>XXX organization’s XXXX XXXXXXXXXX are in research and XXXXXXXXXXX, clinical XXXXXX, production, XXXXXXXXXXXX, XXXXXXXXXXXXX, branding XXX XXXXXX recruitment. Foremost, XXX XXXXXXX invests heavily in XXXXXXXX and XXXXXXXXXXX, XXXXXXXXXX XXXXXXX its lead XXXXXXX XXXXXXXXX of iclaprim, XXX XXXX XXXX XX XXXXX XXXXXXXXX skin XXX skin XXXXXXXXX XXXXXXXXXX (ABSSSI), XXXXXXXX XXXXXXXX bacterial XXXXXXXXX (HABP), XXX ventilor XXXXXXXXXX bacterial pneumonia (XXXX). (Motif XXX, 2019) The XXXXXXX then XXXXXXXX XXXXXXXX trials XX ensure these products are XXXX XXX administration XX XXXXXXXX in situations XXXX as XXXXXXXXX infections and XXXX surgeries. For example, to XXXX, XXX XXXXXXX XXX XXXXXXXXX trials XX nearly X,XXX XXXXXXXX and healthy XXXXXXXXXX XX assess XXX XXXXXXX effectiveness XXX XXXX-XXXXXXX XX iclaprim, XXX main drug XXXXXXXXX. These trials include REVIVE-1, XXXXXX-2 XXX XXXXXXX XXXXXX, XXXXX are trials for XXXXXX, HABP XXX VABP XXXXXXXXXXXX. The XXXXXXX also produces and distributes these XXXXX, XXX is XXXXXXXXXXX for the safe, XXXXXXXXX and XXXX-XXXXXXXXX XXXXXXXXXX and XXXXXXXXXXXX XX their products to XXXXXXXXXXXX XXXX as clinics and hospitals. The company also XXXXX XX certify XXX products XX ensure XXXX XXXX can be XXXXXXXXXXX XXXXXXX, through XXXXXXXXXXXXX processes XXXX XX the Qualified XXXXXXXXXX XXXXXXX Product (XXXX) XXX certification. (Motif Bio, 2015) XXXX, XXX XXXXXXX XXX XX brand its products properly for widespread XXXXXX XXXXXXXXXX, XXXXXXX XXXXX such as XXXXXXXX/XXXXXX XXXXX marketing, XXXXXXXXX XXXXXXXXXXX XXX XXXXXX lectures. XXXXXXX, the company XX XXXXXXXXXXX for talent XXXXXXXXXXX, in order to XXXXXX XXXX a diverse and XXXXXXX XXXX comprising XXXXXXXX researchers, XXXXXXXXXXX, XXX-XXXXXXXXX XXX XXXXXXX XX able to conduct XXXXXXXX XXX XXXXXXXXX research to XXXXXXX novel XXXX-XXXXX-drug-XXXXXXXXX bacteria drugs, as XXXX XX XXXXXXX research in renowned XXXXXXXX such XX Nature XX ensure XXXX XXXXX Bio XXXXX XX XXX XXXXXXXXX of XXXXXXXXXX biopharmaceutical XXXXXXXX.<p></p><p>The XXXXXXXXXXXX XXXXX an XXXXXXXXX XXXX in XXX U.S. XXXXXXXXXX system XX a biopharmaceutical company, and works XXXX XXXXXXXXX, XXXXXXXXXX providers XXX XXX XXXXXXXXXX . XXXXXXX XXXX XXXXX XXXX XXXX 10 XXXXXXX individuals XXXXXXXX XXX XXXXXXXXXXX XX die from XXXX-XXXXXXXXX bacterial XXXXXXXXXX XX XXXX, XXXX 23,XXX deaths XXX year in the X.S. at present. (Czaplewski XXX XXXXXXX, XXXX) XX XXXXXXXX to XXXX worrying XXXXX, XXXXX XXX XXX developed novel XXXX-MRSA XXXXXXXXXX solutions. This XXXXXX a XXX role in XXX U.S. XXXXXXXXXX XXXXXX, by (a) enabling the work XX XXXXXXXXXX providers XXX hospitals, (b) XXXXXXXXXXXXX with XXXXXXXXX to XXXXXX XXXX and efficient drug trials, and (c) XXXXXXX within XXX government’s support schemes and XXXXXXXXXX frameworks XX ensure regulatory compliance. Foremost, XXXXX XXX enables the work XX healthcare XXXXXXXXX XXX XXXXXXXXX by XXXXXXXXX XXXXX XXXXXXXXXX solutions to combat the scourge XX XXXXX-XXXX XXXXXXXXX bacteria. (XXXXXX, XXXX) XXXX XXX XXX XXXXXX of XXXXXXXX XXXX XX save lives, provide more effective XXXXXXXXX, carry out XXXX XXXXXXXXX XXXX XXXXXXXXXX XXXX as surgeries, XXX save XXXXX on XXXXX-drug resistant XXXXXXXXXXXXX XXXXXXXXXX. Secondly, XXXXX XXX XXXXX XXXX hospitals to conduct XXXX and efficient drug trials on XXXXXXXXXX XXXXXXXX. XXXXXXX, the XXXXXXXXXX XXXXXXXX XXXXX XXX’s work through accomodative XXXXXXXXXX frameworks and XXXXXXXXX subsidies.<XX></p><p></p><p><XX></p><p>In XXXXXXXXXX, XXXXX Bio, like other innovative pharmaceutical companies, plays an important XXXX in the X.S. XXXXXXXXXX system XXXXXXX XXX XXXX on XXXXXXXXXXX XXX XXXXXXXXX novel antibiotic XXXXXXXXX to XXXXX-drug resistant XXXXXXXX.<span class="XXXXX-XXXXXXXXX-XXXXX"></span><XX></p> <p><span class="s1"></span> </p> <p><span class="s1"></span> </p> <p><span class="XX"></span> </p> <p><span XXXXX="s1"></span> </p> <p><span class="XX"></span> </p> <p><span XXXXX="s1"></span> </p> <p><span class="s1"></span> </p> <p><span XXXXX="XX"></span> </p> <p><span class="s1"></span> </p> <p><span XXXXX="s1"></span> </p> <p><span class="XX"></span> </p> <p><span XXXXX="s1">References</span></p> <p><span XXXXX="s1"></span> </p> <p><span class="s1">Jackson, N., XXXXXXXXXX, L., & XXXXXXX, X. X. (XXXX). Discovery XXX XXXXXXXXXXX of new antibacterial drugs: XXXXXXXX XXXX experience?.<i>Journal XX Antimicrobial XXXXXXXXXXXX</i>,<i>XX</i>(X), XXXX-1459.</span></p> <p><span class="s1"></span> </p> <p><span class="s1">XXXXX XXX. (XXXX). Phase 3 study XX evaluate safety and XXXXXXXX of XXXXXXXX XXXXXX XXXXXXXXXX for XXXXXX: REVIVE-2 (REVIVE-2).<i>ClinicalTrials. gov identifier XXXXXXXXXXX. XXXXX://clinicaltrials. XXX/ct2/show/NCT02600611</i>.</span></p> <p><span class="XX"></span> </p> <p><span XXXXX="XX">Motif XXX. (XXXX, XXXXXXX XX). XXXXX XXXXX XXX. Retrieved 2019, April<span XXXXX="XXXXX-converted-space"> </span>XX XXXX <a XXXX="https://www.motifbio.XXX/about/"><span XXXXX="XX"></span></a><a href="XXXXX://XXX.motifbio.com/about/">https://www.XXXXXXXX.com/XXXXX/</a></span><span class="XXXXX-XXXXXXXXX-XXXXX"></span></p> <p><span XXXXX="s1"></span> </p> <p><span XXXXX="XX">Schneider, P., XXXXXX, S., & Islam, K. (2003). Iclaprim, a XXXXX diaminopyrimidine with potent activity on trimethoprim XXXXXXXXX and resistant XXXXXXXX.<i>XXXXXXXXXX & medicinal chemistry XXXXXXX</i>,<i>XX</i>(XX), XXXX-4221.</span></p> <p><span XXXXX="s1"></span> </p> <p><span class="s1">Wright, G. X., & XXXXXXXXXX, A. X. (XXXX). XXX strategies XXX XXXXXXXXX multidrug-XXXXXXXXX bacteria.<i>Trends in molecular XXXXXXXX</i>,<i>XX</i>(X), XXX-267.</span></p>">
Attachment #1 Preview
